MetaVia Inc.
MTVA
株式のランク
#32887
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
株価
$1.28
最終同期: 2026-10-20
時価総額
$8.43M
変化（1日）
4.07%
変化（1年）
-21.47%
国
US
取引 MetaVia Inc. (MTVA)
カテゴリー
Healthcare
MetaVia Inc.（MTVA）の利益
Jun 2026 時点の利益 TTM: $-14.45M
MetaVia Inc. の最新の財務報告によると、同社の現在の利益は $-14.45M です。2023 年には $-12.47M の利益を上げ、これは 2022 年の利益 $-13.97M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
MetaVia Inc. の利益の推移（2014 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-14.45M | -47.64% |
| 2024 | $-27.59M | 121.27% |
| 2023 | $-12.47M | -10.72% |
| 2022 | $-13.97M | -8.62% |
| 2021 | $-15.28M | -48.50% |
| 2020 | $-29.68M | 39.25% |
| 2019 | $-21.31M | 37.24% |
| 2018 | $-15.53M | -53.53% |
| 2017 | $-33.42M | 129.09% |
| 2016 | $-14.59M | 61.55% |
| 2015 | $-9.03M | 2,721.56% |
| 2014 | $-320.00K | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -36,614.61% |
US
|
|
| $-3.09B | 21,269.24% |
US
|
|
| $-4.02B | 27,701.44% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -13,603.05% |
NL
|
